ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
13. März 2023 09:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and...
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
13. März 2023 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and...
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
08. März 2023 17:06 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug...
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
08. März 2023 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and...
ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights
14. November 2022 07:00 ET
|
ProMIS Neurosciences Inc.
Closed US$7.4 million private placementAppointed Gail Farfel, Ph.D., as Chief Executive OfficerContinued progress toward investigational new drug (IND) submission for PMN310 to pursue Alzheimer’s...
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement
12. Oktober 2022 07:00 ET
|
ProMIS Neurosciences Inc.
Toronto, Ontario and Cambridge, MA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
13. September 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and...
ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
15. August 2022 17:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on...
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
02. August 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
27. Juli 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...